GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Short Interest

Avadel Pharmaceuticals (STU:AWK) Short Interest


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Avadel Pharmaceuticals's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Short Interest falls into.



Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.